The pharmaceutical industry is under unprecedented pressure. Shorter product lifecycles, increasingly complex therapies, stricter regulatory scrutiny and fragile global supply chains have combined to expose inefficiencies that were once tolerated as “the cost of doing business.” At the same time, patients, regulators and commercial partners expect faster delivery and uncompromising safety.

In this environment, artificial intelligence (AI) and automation are becoming foundational capabilities for building pharmaceutical supply chains that are both resilient and responsive. Nowhere is this more apparent than in secondary packaging and late-stage supply chain operations, areas historically viewed as executional rather than strategic, but which increasingly determine speed to market, compliance outcomes and overall supply continuity.

This article explores how AI and automation are reshaping pharmaceutical supply chains, not as futuristic concepts, but as practical tools already delivering measurable gains in speed, safety and reliability.

From Bottleneck to Backbone: Reframing Secondary Packaging

Secondary packaging sits at a critical junction in the pharmaceutical value chain. It is the point where drug product, regulatory compliance, supply chain orchestration and patient safety converge. Yet for decades, it has been characterised by labour-intensive processes, fragmented data and heavy reliance on manual decision-making.

Global supply chains, particularly for specialty pharma, biotech and niche branded products, are already long and complex. Any disruption at the packaging stage can cascade downstream, delaying market release or interrupting patient supply. As highlighted in recent industry discussions, shortening fulfilment cycles requires tighter integration between packaging operations and the broader supply chain, rather than treating packaging as a standalone activity.